Relay Therapeutics Inc Cash Flow Conversion Efficiency
Relay Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Relay Therapeutics Inc (RLAY) has a cash flow conversion efficiency ratio of -0.080x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-51.11 Million) by net assets ($642.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Relay Therapeutics Inc (2018–2025)
Cash flow conversion efficiency of Relay Therapeutics Inc from 2018 to 2025. This chart illustrates how Relay Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RLAY live share price for real-time trading data and today's change.
Relay Therapeutics Inc Cash Flow Conversion Ratio Explained
Relay Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Relay Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Relay Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Relay Therapeutics Inc (RLAY) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
0.004x |
|
Digitalbridge Group Inc
NYSE:DBRG
|
0.018x |
|
Agilysys Inc
NASDAQ:AGYS
|
0.023x |
|
Stadler Rail AG
SW:SRAIL
|
0.008x |
|
First BanCorp
F:OLWN
|
0.072x |
|
ERMENEGILDO ZEG.DL -0001
F:JN0
|
N/A |
|
Bavarian Nordic
CO:BAVA
|
0.042x |
|
China South Publishing & Media Group Co Ltd
SHG:601098
|
-0.022x |
Annual Cash Flow Conversion Efficiency for Relay Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Relay Therapeutics Inc from 2018 to 2025. Review free cash flow generation of Relay Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $567.06 Million | $-235.46 Million | -0.415x | -29.65% |
| 2024-12-31 | $777.79 Million | $-249.11 Million | -0.320x | +19.80% |
| 2023-12-31 | $752.00 Million | $-300.32 Million | -0.399x | -65.36% |
| 2022-12-31 | $950.22 Million | $-229.49 Million | -0.242x | -191.42% |
| 2021-12-31 | $897.81 Million | $-74.41 Million | -0.083x | +38.28% |
| 2020-12-31 | $763.29 Million | $-102.49 Million | -0.134x | -136.63% |
| 2019-12-31 | $-180.44 Million | $-66.13 Million | 0.367x | -7.88% |
| 2018-12-31 | $-110.93 Million | $-44.13 Million | 0.398x | -- |
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clin… Read more